









Markets
/
Stocks
/
nasdaq-sepn
/

Septerna Inc

SEPN

23.870USD

-0.870-3.52%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.00BMarket Cap

LossP/E TTM



Septerna Inc

23.870

-0.870-3.52%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Septerna Inc

Currency: USD Updated: 2026-03-27

Key Insights

Septerna Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 25 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Septerna Inc's Score

Industry at a Glance

Industry Ranking

25 / 391

Overall Ranking

114 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Septerna Inc Highlights

StrengthsRisks

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 30331.13% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 45.95M.

Undervalued

The company’s latest PE is -21.61, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 45.31M shares, decreasing 7.94% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 989.00 shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

45.500

Target Price

+94.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Septerna Inc is 8.45, ranking 36 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 24.12M, representing a year-over-year increase of 11276.42%, while its net profit experienced a year-over-year increase of 48.05%.

Score

Industry at a Glance

Previous score

8.45

Change



Financials

8.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.15

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Septerna Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Septerna Inc is 6.52, ranking 256 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.61, which is -110.39% below the recent high of 2.24 and -17.39% above the recent low of -25.37.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 25/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Septerna Inc is 8.25, ranking 146 out of 391 in the Biotechnology & Medical Research industry. The average price target is 29.00, with a high of 34.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

45.500

Target Price

+83.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Septerna Inc

SEPN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Septerna Inc is 6.75, ranking 144 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 28.26 and the support level at 21.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.98

Change

-0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.455

Sell

RSI(14)

39.581

Neutral

STOCH(KDJ)(9,3,3)

32.555

Neutral

ATR(14)

1.591

Low Volatility

CCI(14)

-51.687

Neutral

Williams %R

86.865

Oversold

TRIX(12,20)

-0.608

Sell

StochRSI(14)

54.140

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

24.008

Sell

MA10

24.292

Sell

MA20

25.987

Sell

MA50

26.411

Sell

MA100

25.810

Sell

MA200

20.306

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Septerna Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.21%, representing a quarter-over-quarter increase of 0.47%. The largest institutional shareholder is The Vanguard, holding a total of 1.51M shares, representing 3.36% of shares outstanding, with 50.01% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Third Rock Ventures, LLC

10.43M

RA Capital Management, LP

7.00M

Driehaus Capital Management, LLC

4.92M

+5.12%

Samsara BioCapital, LLC

3.15M

Invus Public Equities Advisors, LLC

2.20M

BVF Partners L.P.

4.02M

-8.65%

BlackRock Institutional Trust Company, N.A.

1.32M

+4.97%

The Vanguard Group, Inc.

Star Investors

1.52M

+7.38%

Goldman Sachs & Company, Inc.

1.42M

+0.06%

Avoro Capital Advisors LLC

1.34M

+8.08%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Septerna Inc is 4.58, ranking 79 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.